According to Lexicon Pharmaceuticals 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.528529. At the end of 2022 the company had a P/E ratio of -3.13.
Year | P/E ratio | Change |
---|---|---|
2022 | -3.13 | -51.52% |
2021 | -6.46 | 3.87% |
2020 | -6.22 | -282.8% |
2019 | 3.40 | -158.91% |
2018 | -5.77 | -28.7% |
2017 | -8.10 | -19.78% |
2016 | -10.1 | -96.21% |
2015 | -266 | 5602.54% |
2014 | -4.67 | -48.13% |
2013 | -9.00 | -10.41% |
2012 | -10.0 | 172.55% |
2011 | -3.69 | -10.42% |
2010 | -4.11 | 40.37% |
2009 | -2.93 | 17.24% |
2008 | -2.50 | -49.67% |
2007 | -4.97 | 11.45% |
2006 | -4.46 | -30.4% |
2005 | -6.40 | -38.94% |
2004 | -10.5 | 102.96% |
2003 | -5.17 | 24.52% |
2002 | -4.15 | -74.83% |
2001 | -16.5 |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.